The global flunarizine hydrochloride market is anticipated to grow at considerable CAGR during the forecast period (2022-2028). Rise in the prevalence of the aging population associated with vertigo is expected to drive the global flunarizine hydrochloride market. For instance, according to the data published by National Center for Biotechnology Information (NCBI) in 2021, Vertigo increases with the prevalence of age and other underlying diseases. Based on a survey on the general population, the 1-year prevalence of vertigo is about 5 % and the annual incidence is estimated at 1.4 %. Moreover, dizziness in vertigo is another major factor affecting the population. Further, according to data published by NCBI in 2021, the dizziness associated with vertigo is anticipated to affect up to 15% to 20% of adults annually. Thus , the rise in the prevalence of vertigo is anticipated to propel the growth of the global flunarizine hydrochloride market over the forecast period.
Browse the full report description of “Global Flunarizine Hydrochloride Market Size, Share & Trends Report by Application (Migraine and Vertigo) and by Drug Formulation (Tablets and Capsules) Forecast (2022-2028)” at https://www.omrglobal.com/industry-reports/flunarizine-hydrochloride-market
The key companies operating in the industry are highly inclined towards the adoption of different growth strategies including capacity expansion, partnerships, mergers, and acquisitions, geographical expansions, and product innovations to remain competitive in the market. For instance, in February 2021, Dr. Reddys Laboratories has launched a Fluphenazine hydrochloride tablet under the brand name “Prolixin “approved by US Food and Drug Administration. Fluphenazine is an antipsychotic medication that is used to treat chronic psychoses such as schizophrenia and psychotic symptoms such as hallucinations, delusions, and hostility. Additionally, BDSI is expected to conduct an ELYXYB pediatric study to identify the unmet needs of pediatric and adolescent patients suffering from migraine attacks. According to the Chief Medical officer, the company aims to expand its impact on migraine while staying committed to the patients.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By Application
o By Drug Formulation
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Johnson & Johnson Services Inc., Cipla Ltd., Torrent Pharmaceuticals Ltd., Alkem Laboratories Ltd, and more
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Flunarizine hydrochloride Market Report Segment
By Application
By Drug Formulation
Global Flunarizine hydrochloride Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/flunarizine-hydrochloride-market